CyteSi Validates New NGS Workflow on D1 Platform
The company confirms its sequencing library preparation workflow is compatible with the Turing Biosystem D1 platform.
Updated on Oct. 21, 2026 in Life Sciences
Live Poll
Do you believe automated lab testing improves the efficiency of clinical diagnostics in your area?
CyteSi has successfully validated a new next-generation sequencing library preparation workflow on the Turing Biosystem D1 platform using QIAGEN kits. The validation process, conducted at the Intelligent Biosystems facility, marks a milestone in clinical diagnostics efficiency.
Why it matters
This validation supports clinical diagnostics markets by addressing critical needs for cost control, workflow standardization, and reproducibility. The technological advancement aims to improve operational efficiency in high-throughput genetic testing environments.
The D1 platform processes up to six samples per run using miniaturized, digitized liquid-handling techniques. Validation testing required less than five minutes of hands-on time to complete the library preparation process.
The players
CyteSi
CyteSi is a biotechnology firm headquartered in Menlo Park that specializes in developing advanced sequencing library preparation solutions.
Intelligent Biosystems
Intelligent Biosystems is a laboratory and data-generation facility based in Hangzhou that conducts industrial-scale validation testing.
QIAGEN
QIAGEN is a global provider of sample and assay technologies used widely in molecular diagnostics and life sciences research.
The details
Intelligent Biosystems performed the testing in Hangzhou, China, by applying industrial-scale biological data-generation capabilities. The integration of QIAGEN kits with the D1 system effectively automates complex preparation steps to streamline laboratory workflows.
Timeline
October 21, 2026: CyteSi announced the successful validation of the NGS workflow.
The Big Picture
This development aligns with the clinical diagnostics market's standards for NGS workflow efficiency. It advances the discipline by shifting away from labor-intensive preparation toward digitized, automated systems.
This workflow could lead to lower costs for genetic diagnostic testing and faster results for patients. By simplifying library preparation, clinical labs may see significant improvements in sample throughput and operational turnaround.
The takeaway
Technological advancements like the D1 platform signal a broader industry shift toward digitizing manual laboratory processes. Future NGS workflow adoption will likely rely on these types of validated kit partnerships to ensure cross-platform compatibility.
Further reading
Learn more about the latest innovations in Life Sciences.
Source note: This article includes information reported by ELE Times.
Live Poll
Do you believe automated lab testing improves the efficiency of clinical diagnostics in your area?
